1/12/2021 6:55:52 AM
Merck: FDA Accepts For Priority Review A BLA For V114 For Prevention Of Invasive Pneumococcal Disease
12/23/2020 7:18:34 AM
Merck Announces Supply Deal For Initial Doses Of Investigational Biological Therapy For COVID-19
12/17/2020 7:18:56 AM
Merck Says FDA Grants Priority Review To SBLA For KEYTRUDA Plus Chemotherapy
12/16/2020 7:07:04 AM
Merck Says Pivotal Phase 3 KEYNOTE-775/Study 309 Trial Met Its Dual Primary Endpoints
12/11/2020 7:37:10 AM
Merck Says CHMP Of EMA Adopted Positive Opinion Recommending Approval Of KEYTRUDA
12/2/2020 8:22:28 AM
Merck Divests Its Direct Holding In Moderna
11/23/2020 7:21:44 AM
Merck Submits Applications To FDA And EMA For Licensure Of V114
11/23/2020 7:20:20 AM
Merck To Acquire OncoImmune For An Upfront Payment Of $425 Mln